Technical Analysis for BNOX - Bionomics Limited

Grade Last Price % Change Price Change
F 2.25 -6.25% -0.15
BNOX closed down 6.25 percent on Friday, March 24, 2023, on 19 percent of normal volume. The bears made the stock sink to a new 52-week low. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
Narrow Range Bar Range Contraction 0.00%
New 52 Week Low Weakness 0.00%
Wide Bands Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Down 5 Days in a Row Weakness 0.00%
Oversold Stochastic Weakness 0.00%
New 52 Week Closing Low Bearish -6.25%
New 52 Week Low Weakness -6.25%

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Fell Below Previous Day's Low about 12 hours ago
New 52 Week Low about 12 hours ago
Down 5% about 12 hours ago
60 Minute Opening Range Breakdown about 14 hours ago
Down 3% about 14 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Bionomics Limited Description

Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia and the United States. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which has completed phase 2 clinical trial for the treatment of social anxiety disorder and post-traumatic stress disorder. It also develops BNC375, a small molecule therapeutics for the treatment of cognitive impairment in Alzheimer's disease; BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, a vascular disrupting agent, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer, and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. Bionomics Limited has a licensing agreement with Merck & Co., Inc. The company was incorporated in 1996 and is based in Eastwood, Australia.


Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Clinical Medicine Drugs Cancer Treatment Stem Cell Monoclonal Antibodies Alzheimer's Disease Antineoplastic Drugs Central Nervous System Disorders Post Traumatic Stress Disorder Treatment Of Central Nervous System Disorders Camidanlumab Tesirine Cognitive Impairment Anxiolytics Milatuzumab

Is BNOX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 12.99
52 Week Low 2.2001
Average Volume 141,926
200-Day Moving Average 6.40
50-Day Moving Average 3.61
20-Day Moving Average 3.05
10-Day Moving Average 2.61
Average True Range 0.62
RSI 35.48
ADX 30.07
+DI 27.34
-DI 16.60
Chandelier Exit (Long, 3 ATRs) 5.86
Chandelier Exit (Short, 3 ATRs) 4.05
Upper Bollinger Bands 4.26
Lower Bollinger Band 1.83
Percent B (%b) 0.17
BandWidth 80.04
MACD Line -0.39
MACD Signal Line -0.32
MACD Histogram -0.0637
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.59
Resistance 3 (R3) 2.61 2.52 2.53
Resistance 2 (R2) 2.52 2.43 2.51 2.51
Resistance 1 (R1) 2.38 2.38 2.34 2.36 2.49
Pivot Point 2.29 2.29 2.27 2.28 2.29
Support 1 (S1) 2.16 2.21 2.11 2.14 2.01
Support 2 (S2) 2.07 2.15 2.06 1.99
Support 3 (S3) 1.93 2.07 1.97
Support 4 (S4) 1.91